413 related articles for article (PubMed ID: 28963773)
1. In-vitro effect of pembrolizumab on different T regulatory cell subsets.
Toor SM; Syed Khaja AS; Alkurd I; Elkord E
Clin Exp Immunol; 2018 Feb; 191(2):189-197. PubMed ID: 28963773
[TBL] [Abstract][Full Text] [Related]
2. Staphylococcus aureus convert neonatal conventional CD4(+) T cells into FOXP3(+) CD25(+) CD127(low) T cells via the PD-1/PD-L1 axis.
Rabe H; Nordström I; Andersson K; Lundell AC; Rudin A
Immunology; 2014 Mar; 141(3):467-81. PubMed ID: 24708420
[TBL] [Abstract][Full Text] [Related]
3. Immune suppression in premalignant respiratory papillomas: enriched functional CD4+Foxp3+ regulatory T cells and PD-1/PD-L1/L2 expression.
Hatam LJ; Devoti JA; Rosenthal DW; Lam F; Abramson AL; Steinberg BM; Bonagura VR
Clin Cancer Res; 2012 Apr; 18(7):1925-35. PubMed ID: 22322668
[TBL] [Abstract][Full Text] [Related]
4. Low expressions of PD-L1 and CTLA-4 by induced CD4
Zhao L; Zhou X; Zhou X; Wang H; Gu L; Ke Y; Zhang M; Ji X; Yang X
Cytokine; 2020 Sep; 133():155119. PubMed ID: 32535334
[TBL] [Abstract][Full Text] [Related]
5. Pembrolizumab Interferes with the Differentiation of Human FOXP3
Sasidharan Nair V; Toor SM; Taouk G; Pfister G; Ouararhni K; Alajez NM; Elkord E
J Immunol; 2020 Jan; 204(1):199-211. PubMed ID: 31801817
[TBL] [Abstract][Full Text] [Related]
6. Preferential accumulation of regulatory T cells with highly immunosuppressive characteristics in breast tumor microenvironment.
Syed Khaja AS; Toor SM; El Salhat H; Faour I; Ul Haq N; Ali BR; Elkord E
Oncotarget; 2017 May; 8(20):33159-33171. PubMed ID: 28388539
[TBL] [Abstract][Full Text] [Related]
7. Effect of pembrolizumab on CD4
Toor SM; Sasidharan Nair V; Pfister G; Elkord E
Clin Exp Immunol; 2019 Jun; 196(3):345-352. PubMed ID: 30693485
[TBL] [Abstract][Full Text] [Related]
8. Biophysical and Immunological Characterization and
Hutchins B; Starling GC; McCoy MA; Herzyk D; Poulet FM; Dulos J; Liu L; Kang SP; Fayadat-Dilman L; Hsieh M; Andrews CL; Ayanoglu G; Cullen C; Malefyt RW; Kastelein RA; Saux SL; Lee J; Li S; Malashock D; Sadekova S; Soder G; van Eenennaam H; Willingham A; Yu Y; Streuli M; Carven GJ; van Elsas A
Mol Cancer Ther; 2020 Jun; 19(6):1298-1307. PubMed ID: 32229606
[TBL] [Abstract][Full Text] [Related]
9. High programmed death 1 expression on T cells in aplastic anemia.
Zhao W; Zhang Y; Zhang P; Yang J; Zhang L; He A; Zhang W; Hideto T
Immunol Lett; 2017 Mar; 183():44-51. PubMed ID: 28153603
[TBL] [Abstract][Full Text] [Related]
10. Foxp3
Liu L; Zhang Q; Chen P; Guo N; Song A; Huang X; Xia W; Li L; Moog C; Wu H; Su B; Zhang T
BMC Immunol; 2019 Oct; 20(1):38. PubMed ID: 31651258
[TBL] [Abstract][Full Text] [Related]
11. Human CD8
Machicote A; Belén S; Baz P; Billordo LA; Fainboim L
Front Immunol; 2018; 9():2788. PubMed ID: 30555473
[TBL] [Abstract][Full Text] [Related]
12. Cells with Treg-specific FOXP3 demethylation but low CD25 are prevalent in autoimmunity.
Ferreira RC; Simons HZ; Thompson WS; Rainbow DB; Yang X; Cutler AJ; Oliveira J; Castro Dopico X; Smyth DJ; Savinykh N; Mashar M; Vyse TJ; Dunger DB; Baxendale H; Chandra A; Wallace C; Todd JA; Wicker LS; Pekalski ML
J Autoimmun; 2017 Nov; 84():75-86. PubMed ID: 28747257
[TBL] [Abstract][Full Text] [Related]
13. Frequencies of regulatory subsets of CD4
Saikia L; Deka T; Deori P; Roy R; Hussain ME; Nath R
Indian J Med Microbiol; 2019; 37(3):370-375. PubMed ID: 32003335
[TBL] [Abstract][Full Text] [Related]
14. Functional heterogeneity of circulating T regulatory cell subsets in breast cancer patients.
Ostapchuk YO; Perfilyeva YV; Kustova EA; Urazalieva NT; Omarbaeva NA; Talaeva SG; Belyaev NN
Breast Cancer; 2018 Nov; 25(6):687-697. PubMed ID: 29797233
[TBL] [Abstract][Full Text] [Related]
15. Phenotypic and functional characteristics of CD4+ CD39+ FOXP3+ and CD4+ CD39+ FOXP3neg T-cell subsets in cancer patients.
Schuler PJ; Schilling B; Harasymczuk M; Hoffmann TK; Johnson J; Lang S; Whiteside TL
Eur J Immunol; 2012 Jul; 42(7):1876-85. PubMed ID: 22585562
[TBL] [Abstract][Full Text] [Related]
16. The characteristic profiles of PD-1 and PD-L1 expressions and dynamic changes during treatment in active tuberculosis.
Shen L; Shi H; Gao Y; Ou Q; Liu Q; Liu Y; Wu J; Zhang W; Fan L; Shao L
Tuberculosis (Edinb); 2016 Dec; 101():146-150. PubMed ID: 27865385
[TBL] [Abstract][Full Text] [Related]
17. Human umbilical vein endothelial cells promote the inhibitory activation of CD4(+)CD25(+)Foxp3(+) regulatory T cells via PD-L1.
Chen WJ; Hu XF; Yan M; Zhang WY; Mao XB; Shu YW
Atherosclerosis; 2016 Jan; 244():108-12. PubMed ID: 26615520
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of T-cell-mediated immune response via the PD-1/ PD-L1 axis in cholangiocarcinoma cells.
Suriyo T; Fuangthong M; Artpradit C; Ungtrakul T; Sricharunrat T; Taha F; Satayavivad J
Eur J Pharmacol; 2021 Apr; 897():173960. PubMed ID: 33617828
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of PD-1 blockade in cervical cancer is related to a CD8
Heeren AM; Rotman J; Stam AGM; Pocorni N; Gassama AA; Samuels S; Bleeker MCG; Mom CH; Zijlmans HJMAA; Kenter GG; Jordanova ES; de Gruijl TD
J Immunother Cancer; 2019 Feb; 7(1):43. PubMed ID: 30755279
[TBL] [Abstract][Full Text] [Related]
20. Combining FoxP3 and Helios with GARP/LAP markers can identify expanded Treg subsets in cancer patients.
Abd Al Samid M; Chaudhary B; Khaled YS; Ammori BJ; Elkord E
Oncotarget; 2016 Mar; 7(12):14083-94. PubMed ID: 26885615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
